Search

Your search keyword '"Mohile, Nimish A."' showing total 365 results
Start Over Author "Mohile, Nimish A."
365 results on '"Mohile, Nimish A."'

7. Practical guidance for telemedicine use in neuro-oncology

Author

Strowd, Roy E, Dunbar, Erin M, Gan, Hui K, Kurz, Sylvia, Jordan, Justin T, Mandel, Jacob J, Mohile, Nimish A, Nevel, Kathryn S, Taylor, Jennie W, Ullrich, Nicole J, Welch, Mary R, Wasilewski, Andrea, and Mrugala, Maciej M

Subjects
Biomedical and Clinical Sciences, Neurosciences, Oncology and Carcinogenesis, Clinical Research, Networking and Information Technology R&D (NITRD), Health Services, Rural Health, Good Health and Well Being, telemedicine, telehealth, neurological examination, clinical trials, caregiver, Oncology and carcinogenesis
Abstract

While the COVID-19 pandemic has catalyzed the expansion of telemedicine into nearly every specialty of medicine, few articles have summarized current practices and recommendations for integrating virtual care in the practice of neuro-oncology. This article identifies current telemedicine practice, provides practical guidance for conducting telemedicine visits, and generates recommendations for integrating virtual care into neuro-oncology practice. Practical aspects of telemedicine are summarized including when to use and not use telemedicine, how to conduct a virtual visit, who to include in the virtual encounter, unique aspects of telehealth in neuro-oncology, and emerging innovations.

Published
2022

8. Contemporary Neuroscience Core Curriculum for Medical Schools

Author

Gelb, Douglas J, Kraakevik, Jeff, Safdieh, Joseph E, Agarwal, Sachin, Odia, Yazmin, Govindarajan, Raghav, Quick, Adam, Soni, Madhu, Bickel, Jennifer, Gamaldo, Charlene, Hannon, Peter, Hatch, Hayden AM, Hernandez, Christian, Merlin, Lisa R, Noble, James M, Reyes-Iglesias, Yolanda, Marie E Salas, Rachel, Sandness, David James, Treat, Lauren, Benameur, Karima, Brown, Robert D, DeLuca, Gabriele C, Garg, Neeta, Goldstein, Larry B, Gutmann, Laurie, Henchcliffe, Claire, Hessler, Amy, Jordan, Justin T, Kilgore, Shannon M, Khan, Jaffar, Levin, Kerry H, Mohile, Nimish A, Nevel, Kathryn S, Roberts, Kirk, Said, Rana R, Simpson, Ericka P, Sirven, Joseph I, Smith, A Gordon, Southerland, Andrew Mebane, and Wilson, Rujuta Bhatt

Subjects
Neurosciences, Quality Education, AAN Undergraduate Education Subcommittee, AAN Education Committee, Clinical Sciences, Cognitive Sciences, Neurology & Neurosurgery
Abstract

Medical students need to understand core neuroscience principles as a foundation for their required clinical experiences in neurology. In fact, they need a solid neuroscience foundation for their clinical experiences in all other medical disciplines also, because the nervous system plays such a critical role in the function of every organ system. Due to the rapid pace of neuroscience discoveries, it is unrealistic to expect students to master the entire field. It is also unnecessary, as students can expect to have ready access to electronic reference sources no matter where they practice. In the pre-clerkship phase of medical school, the focus should be on providing students with the foundational knowledge to use those resources effectively and interpret them correctly. This article describes an organizational framework for teaching the essential neuroscience background needed by all physicians. This is particularly germane at a time when many medical schools are re-assessing traditional practices and instituting curricular changes such as competency-based approaches, earlier clinical immersion, and increased emphasis on active learning. This article reviews factors that should be considered when developing the pre-clerkship neuroscience curriculum, including goals and objectives for the curriculum, the general topics to include, teaching and assessment methodology, who should direct the course, and the areas of expertise of faculty who might be enlisted as teachers or content experts. These guidelines were developed by a work group of experienced educators appointed by the Undergraduate Education Subcommittee (UES) of the American Academy of Neurology (AAN). They were then successively reviewed, edited, and approved by the entire UES, the AAN Education Committee, and the AAN Board of Directors.

Published
2021

9. Clinical neuro-oncology for the neurologist.

Author

Lukas, Rimas V, Taylor, Jennie W, Kurz, Sylvia C, and Mohile, Nimish A

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Rare Diseases, Hematology, Neurosciences, Clinical Research, Brain Disorders, Cancer, Brain Cancer
Abstract

Purpose of reviewNeuro-oncologic patients are routinely encountered in clinical practice. Neuro-oncology is a rapidly evolving field, so understanding the most classic paradigms and contemporary advances will optimize patient care.Recent findingsWe discuss the recent reclassification of tumors via molecular characteristics as it applies to direct clinical practice and review the contemporary standard of care for infiltrating gliomas, meningiomas, brain metastases, and CNS lymphoma.SummaryWe provide a straightforward primer on neuro-oncology with a focus on the brain tumors most commonly encountered by the adult neurologist and a clear emphasis on clinically relevant points including those which have recently become incorporated into our standard management. We cite key reviews to allow interested readers an opportunity to gain a more comprehensive understanding of specific topics.

Published
2020

10. A randomized controlled phase III study of VB-111 combined with bevacizumab vs bevacizumab monotherapy in patients with recurrent glioblastoma (GLOBE)

Author

Cloughesy, Timothy F, Brenner, Andrew, de Groot, John F, Butowski, Nicholas A, Zach, Leor, Campian, Jian L, Ellingson, Benjamin M, Freedman, Laurence S, Cohen, Yael C, Lowenton-Spier, Noa, Minei, Tamar Rachmilewitz, Shmueli, Shifra Fain, Avgeropoulos, Nicholas, Beck, Joseph, Benkers, Tara, Bokstein, Felix, Burton, Eric, Butowski, Nicholas, Campian, Jian, Carrillo, Jose, Cloughesy, Timothy, de Groot, John, De Robles, Paula, Drappatz, Jan, Dunbar, Irine, Fink, Karen, Groves, Morris, Han, Xiaosi, Adila, Hormigo, Jensen, Randy, Kowalska, Agnieszka, Kumthekar, Pyriya, Lee, Mijung, Lesser, Glenn, Lossos, Alexander, Lukas, Rimas, Macdonald, David, Mammoser, Aaron, Mechtler, Laszlo, Mohile, Nimish, Nagpal, Seema, Nicholas, Garth, Kreisl, Teri, Pan, Edward, Peak, Scott, Pearlman, Michael, Perry, James, Peterson, Richard, Piccioni, David, Robins, Henry, Ronan, Lara, Salacz, Michael, Schiff, David, Tran, David, Tzuk-Shina, Tzahala, Walbert, Tobias, Wen, Patrick, Youst, Shlomit, and Y, Wen Patrick

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Brain Disorders, Neurosciences, Brain Cancer, Cancer, Rare Diseases, Clinical Research, Clinical Trials and Supportive Activities, 6.2 Cellular and gene therapies, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Angiogenesis Inhibitors, Antineoplastic Combined Chemotherapy Protocols, Bevacizumab, Brain Neoplasms, Glioblastoma, Humans, Progression-Free Survival, Treatment Outcome, anti-angiogenesis, gene therapy, glioblastoma VB-111, viral immuno-oncology, GLOBE Study Investigators, VB-111, glioblastoma, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract

BackgroundOfranergene obadenovec (VB-111) is an anticancer viral therapy that demonstrated in a phase II study a survival benefit for patients with recurrent glioblastoma (rGBM) who were primed with VB-111 monotherapy that was continued after progression with concomitant bevacizumab.MethodsThis pivotal phase III randomized, controlled trial compared the efficacy and safety of upfront combination of VB-111 and bevacizumab versus bevacizumab monotherapy. Patients were randomized 1:1 to receive VB-111 1013 viral particles every 8 weeks in combination with bevacizumab 10 mg/kg every 2 weeks (combination arm) or bevacizumab monotherapy (control arm). The primary endpoint was overall survival (OS), and secondary endpoints were objective response rate (ORR) by Response Assessment in Neuro-Oncology (RANO) criteria and progression-free survival (PFS).ResultsEnrolled were 256 patients at 57 sites. Median exposure to VB-111 was 4 months. The study did not meet its primary or secondary goals. Median OS was 6.8 versus 7.9 months in the combination versus control arm (hazard ratio, 1.20; 95% CI: 0.91-1.59; P = 0.19) and ORR was 27.3% versus 21.9% (P = 0.26). A higher rate of grades 3-5 adverse events was reported in the combination arm (67% vs 40%), mainly attributed to a higher rate of CNS and flu-like/fever events. Trends for improved survival with combination treatment were seen in the subgroup of patients with smaller tumors and in patients who had a posttreatment febrile reaction.ConclusionsIn this study, upfront concomitant administration of VB-111 and bevacizumab failed to improve outcomes in rGBM. Change of treatment regimen, with the lack of VB-111 monotherapy priming, may explain the differences from the favorable phase II results.Clinical trials registrationNCT02511405.

Published
2020

11. Efficacy of Adding Veliparib to Temozolomide for Patients With MGMT-Methylated Glioblastoma: A Randomized Clinical Trial.

Author

Sarkaria, Jann N., Ballman, Karla V., Kizilbash, Sani H., Sulman, Erik P., Giannini, Caterina, Friday, Bret B., Butowski, Nicholas A., Mohile, Nimish A., Piccioni, David E., Battiste, James D., Drappatz, Jan, Campian, Jian L., Mashru, Sandeep, Jaeckle, Kurt A., O'Brien, Barbara J., Dixon, Jesse G., Kabat, Brian F., Laack, Nadia L., Hu, Leland S., and Kaufmann, Timothy

Published
2024
Full Text
View/download PDF

13. Efficacy of trastuzumab deruxtecan in treating HER2-low breast cancer leptomeningeal metastasis: a case report.

Author

Kharel, Zeni, Stanford, Sarah, Hemminger, Lauryn E, Schmidt, Tyler, Hardy, Sara J, Zittel, Jason, Mohile, Nimish A, and Dhakal, Ajay

Abstract

Abstract accepted at SABCS 2023, poster presented at SABCS 2023 We report the efficacy of trastuzumab deruxtecan (T-DXd) in treating human epidermal growth factor receptor 2 (HER2) low, type ID leptomeningeal breast cancer (LMD) (with positive cerebrospinal fluid [CSF] cytology and hydrocephalus as the only abnormal imaging finding) and the diagnostic and monitoring utilization of a novel microfluidic platform called CNSide™. Breast cancer LMD is associated with poor prognosis, and effective treatments are lacking. Our case highlights two crucial aspects related to the treatment and monitoring of breast cancer LMD. First, T-DXd was chosen based on immunocytochemistry (IHC) data from CSF malignant cells and follow-up revealed effectiveness of T-DXd in treating HER2-low LMD. While the efficacy of T-DXd has been established in treating metastatic HER2-low breast cancer, our case represents, to our knowledge, the first demonstration of T-DXd's effectiveness in HER2-low breast cancer LMD. Second, since this is type 1D LMD with absence of unequivocal measurable radiological disease in both the central nervous system (CNS) and extra-CNS, we employed a novel microfluidic CSF assay to monitor disease response. This novel assay outperformed standard CSF cytology in our case. There is an urgent need to develop CSF tumor cell assessment tool that surpasses the capabilities of conventional CSF cytology. Article highlights T-DXd is highly efficacious in treating HER2 low, leptomeningeal breast cancer. CSF CNSide™ assay utilizes a microfluidic platform and an antibody capture method to capture tumor cells. It uses the same principles used for detecting circulating tumor cells in peripheral blood. CNSide™ assay has a sensitivity of 100% compared with standard CSF cytology which has a sensitivity of 50–60%. CNSide™ assay can be used for facilitating receptor status characterization and guiding treatment. Our case demonstrates efficacy of T-DXd in treating HER2 low leptomeningeal breast cancer and also highlights the clinical utility of CNSide™ assay. Our case aligns well with the emerging literature about the efficacy of T-DXd in treating metastatic HER2-low disease. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

18. Myeloablative Vs. Non-Myeloablative Consolidation for Primary Central Nervous System Lymphoma: Results of Alliance 51101

Author

Batchelor, Tracy T, primary, Giri, Sharmila, additional, Ruppert, Amy S., additional, Geyer, Susan, additional, Smith, Scott E, additional, Mohile, Nimish, additional, Swinnen, Lode J, additional, Friedberg, Jonathan W., additional, Kahl, Brad S., additional, Bartlett, Nancy L., additional, Hsi, Eric D., additional, Cheson, Bruce David, additional, Wagner-Johnston, Nina D, additional, Nayak, Lakshmi, additional, Leonard, John P., additional, and Rubenstein, James Louis, additional

Published
2024
Full Text
View/download PDF

24. Caregiving burden of informal caregivers of older adults with advanced cancer: The effects of rurality and education

Author

Xu, Huiwen, Kadambi, Sindhuja, Mohile, Supriya G., Yang, Shuhan, Kehoe, Lee A., Wells, Megan, Culakova, Eva, Kamen, Charles, Obrecht, Spencer, Mohamed, Mostafa, Gilmore, Nikesha J., Magnuson, Allison, Grossman, Valerie Aarne, Hopkins, Judith O., Geer, Jodi, Berenberg, Jeffrey, Mustian, Karen, Cupertino, Anapaula, Mohile, Nimish, and Loh, Kah Poh

Published
2021
Full Text
View/download PDF

25. Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial

Author

Weller, Michael, Butowski, Nicholas, Tran, David D, Recht, Lawrence D, Lim, Michael, Hirte, Hal, Ashby, Lynn, Mechtler, Laszlo, Goldlust, Samuel A, Iwamoto, Fabio, Drappatz, Jan, O'Rourke, Donald M, Wong, Mark, Hamilton, Mark G, Finocchiaro, Gaetano, Perry, James, Wick, Wolfgang, Green, Jennifer, He, Yi, Turner, Christopher D, Yellin, Michael J, Keler, Tibor, Davis, Thomas A, Stupp, Roger, Sampson, John H, investigators, ACT IV trial, Campian, Jian, Recht, Lawrence, Goldlust, Samuel, Becker, Kevin, Barnett, Gene, Nicholas, Garth, Desjardins, Annick, Benkers, Tara, Wagle, Naveed, Groves, Morris, Kesari, Santosh, Horvath, Zsolt, Merrell, Ryan, Curry, Richard, O'Rourke, James, Schuster, David, Mrugala, Maciej, Jensen, Randy, Trusheim, John, Lesser, Glenn, Belanger, Karl, Sloan, Andrew, Purow, Benjamin, Fink, Karen, Raizer, Jeffrey, Schulder, Michael, Nair, Suresh, Peak, Scott, Brandes, Alba, Mohile, Nimish, Landolfi, Joseph, Olson, Jon, Jennens, Ross, DeSouza, Paul, Robinson, Bridget, Crittenden, Marka, Shih, Kent, Flowers, Alexandra, Ong, Shirley, Connelly, Jennifer, Hadjipanayis, Costas, Giglio, Pierre, Mott, Frank, Mathieu, David, Lessard, Nathalie, Sepulveda, Sanchez Juan, Lövey, József, Wheeler, Helen, Inglis, Po-Ling, Hardie, Claire, Bota, Daniela, Lesniak, Maciej, Portnow, Jana, Frankel, Bruce, Junck, Larry, Thompson, Reid, Berk, Lawrence, McGhie, John, Macdonald, David, Saran, Frank, Soffietti, Riccardo, Blumenthal, Deborah, and de, Sá Barreto Costa Marcos André

Subjects
Brain Disorders, Rare Diseases, Clinical Research, Cancer, Clinical Trials and Supportive Activities, Neurosciences, Brain Cancer, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Brain Neoplasms, Cancer Vaccines, Dacarbazine, Disease-Free Survival, Dose-Response Relationship, Drug, Double-Blind Method, Drug Administration Schedule, ErbB Receptors, Female, Follow-Up Studies, Gene Expression Regulation, Neoplastic, Glioblastoma, Humans, Internationality, Kaplan-Meier Estimate, Male, Middle Aged, Patient Selection, Proportional Hazards Models, Survival Analysis, Temozolomide, Time Factors, Treatment Outcome, Vaccines, Subunit, Young Adult, ACT IV trial investigators, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

BackgroundRindopepimut (also known as CDX-110), a vaccine targeting the EGFR deletion mutation EGFRvIII, consists of an EGFRvIII-specific peptide conjugated to keyhole limpet haemocyanin. In the ACT IV study, we aimed to assess whether or not the addition of rindopepimut to standard chemotherapy is able to improve survival in patients with EGFRvIII-positive glioblastoma.MethodsIn this randomised, double-blind, phase 3 trial, we recruited patients aged 18 years and older with glioblastoma from 165 hospitals in 22 countries. Eligible patients had newly diagnosed glioblastoma confirmed to express EGFRvIII by central analysis, and had undergone maximal surgical resection and completion of standard chemoradiation without progression. Patients were stratified by European Organisation for Research and Treatment of Cancer recursive partitioning analysis class, MGMT promoter methylation, and geographical region, and randomly assigned (1:1) with a prespecified randomisation sequence (block size of four) to receive rindopepimut (500 μg admixed with 150 μg GM-CSF) or control (100 μg keyhole limpet haemocyanin) via monthly intradermal injection until progression or intolerance, concurrent with standard oral temozolomide (150-200 mg/m2 for 5 of 28 days) for 6-12 cycles or longer. Patients, investigators, and the trial funder were masked to treatment allocation. The primary endpoint was overall survival in patients with minimal residual disease (MRD; enhancing tumour

Published
2017

26. A state-of-the-art review and guidelines for tumor treating fields treatment planning and patient follow-up in glioblastoma

Author

Trusheim, John, Dunbar, Erin, Battiste, James, Iwamoto, Fabio, Mohile, Nimish, Damek, Denise, Bota, Daniela A, and Connelly, Jennifer

Subjects
Brain Disorders, Rare Diseases, Cancer, Neurosciences, Brain Cancer, Patient Safety, Good Health and Well Being, Algorithms, Antineoplastic Agents, Alkylating, Brain Neoplasms, Combined Modality Therapy, Dacarbazine, Female, Follow-Up Studies, Glioblastoma, Humans, Magnetic Field Therapy, Magnetic Resonance Imaging, Male, Practice Guidelines as Topic, Temozolomide, NovoTAL, TTFields, alternating electric fields, glioblastoma, guidelines, response assessment, treatment planning, tumor treating fields
Abstract

Tumor treating fields (TTFields) are an integral treatment modality in the management of glioblastoma and extend overall survival when combined with maintenance temozolomide in newly diagnosed patients. Complexities exist regarding correct selection of imaging sequences with which to perform TTFields treatment planning. Guidelines are warranted first, to facilitate treatment planning standardization across medical disciplines and institutions, to ensure optimal TTFields delivery to the tumor and peritumoral brain zone while maximizing patient safety, and also to mitigate the risk of premature cessation of a potentially beneficial treatment. This summary guideline outlines methods for starting patients on TTFields, for monitoring patient response to therapy and provides a framework for evaluating when therapy should be re-planned, based on the extent of sequential imaging changes.

Published
2017

31. Pilot trial testing the effects of exercise on chemotherapy-induced peripheral neurotoxicity (CIPN) and the interoceptive brain system

Author

Kleckner, Ian R., primary, Manuweera, Thushini, additional, Lin, Po-Ju, additional, Chung, Kaitlin H., additional, Kleckner, Amber S., additional, Gewandter, Jennifer S., additional, Culakova, Eva, additional, Tivarus, Madalina E., additional, Dunne, Richard F., additional, Loh, Kah Poh, additional, Mohile, Nimish A., additional, Kesler, Shelli R., additional, and Mustian, Karen M., additional

Published
2024
Full Text
View/download PDF

32. Practical guidance for direct oral anticoagulant use in the treatment of venous thromboembolism in primary and metastatic brain tumor patients

Author

Ranjan, Surabhi, primary, Leung, Denise, additional, Ghiaseddin, Ashley P., additional, Taylor, Jennie W., additional, Lobbous, Mina, additional, Dhawan, Andrew, additional, Budhu, Joshua A., additional, Coffee, Elizabeth, additional, Melnick, Kaitlyn, additional, Chowdhary, Sajeel A., additional, Lu‐Emerson, Christine, additional, Kurz, Sylvia C., additional, Burke, Joy E., additional, Lam, Keng, additional, Patel, Mallika P., additional, Dunbar, Erin M., additional, Mohile, Nimish A., additional, and Peters, Katherine B., additional

Published
2024
Full Text
View/download PDF

36. Contributors List

Author

Ambady, Prakash, primary, Bagley, Stephen J., additional, Blakeley, Jaishri, additional, Brooks, Taylor, additional, Bussière, Marc R., additional, Campian, Jian L., additional, Chan, Michael D., additional, Chukwueke, Ugonma N., additional, Cramer, Christina K., additional, Couture, Daniel E., additional, Cummings, Tiffany L., additional, Dahiya, Sonika, additional, Blank, Peter de, additional, Diaz-Arias, Luisa A., additional, Franchino, Federica, additional, Franke, Jennifer L., additional, Geer, Carol Parks, additional, Gerstner, Elizabeth R., additional, Grossman, Stuart, additional, Henderson, Jacob J., additional, Henke, Lauren L., additional, Holdhoff, Matthias, additional, Hsu, Wesley, additional, Huang, Jiayi, additional, Jackson, Christina, additional, Jordan, Justin T., additional, Kamson, David Olayinka, additional, Kassem, Ahmad N., additional, Kim, Albert E., additional, Kim, Teddy E., additional, Knox, Molly, additional, Kram, David E., additional, Kumthekar, Priya, additional, Langmead, Shannon, additional, Laxton, Adrian W., additional, Lebow, Emily S., additional, Lim, Michael, additional, Lim-Fat, Mary Jane, additional, Ly, K. Ina, additional, Mancone, Sarah E., additional, Mohile, Nimish, additional, Mrugala, Maciej M., additional, Nechtman, Carl M., additional, Pathak, Sapna, additional, Netto, Joao Prola, additional, Peereboom, David M., additional, Pellerino, Alessia, additional, Probasco, John C., additional, Pruitt, Amy, additional, Ramkissoon, Shakti, additional, Robinson, David Wayne, additional, Romo, Carlos G., additional, Rudà, Roberta, additional, Shen, Colette, additional, Shih, Helen A., additional, Silvia, Mary, additional, Sivakumar, Ananyaa, additional, Soffietti, Riccardo, additional, Soike, Michael H., additional, Strowd, Roy E., additional, Sud, Shivani, additional, Szidonya, Laszlo, additional, Tatter, Stephen B., additional, Thakkar, Jigisha, additional, Uluc, Kutluay, additional, Valencia-Sanchez, Cristina, additional, Vaughn, Courtney M., additional, Vu, Thuy M., additional, Wasilewski, Andrea, additional, Wen, Patrick Y., additional, and Williams, Michelle Marie, additional

Published
2021
Full Text
View/download PDF

38. Wireless transcutaneous electric nerve stimulation (TENS) for chronic chemotherapy-induced peripheral neuropathy (CIPN): a proof-of-concept randomized clinical trial

Author

Gewandter, Jennifer S., primary, Culakova, Eva, additional, Davis, Jenae N., additional, Gada, Umang, additional, Guido, Joseph J., additional, Bearden, James D., additional, Burnette, Brain, additional, Shah, Dhaval, additional, Morrow, Gary, additional, Mustian, Karen, additional, Sluka, Kathleen, additional, and Mohile, Nimish, additional

Published
2023
Full Text
View/download PDF

41. Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial

Author

Butowski, Nicholas, Campian, Jian, Recht, Lawrence, Lim, Michael, Ashby, Lynn, Drappatz, Jan, Hirte, Hal, Iwamoto, Fabio, Mechtler, Laszlo, Goldlust, Samuel, Becker, Kevin, Barnett, Gene, Nicholas, Garth, Desjardins, Annick, Benkers, Tara, Wagle, Naveed, Groves, Morris, Kesari, Santosh, Horvath, Zsolt, Merrell, Ryan, Curry, Richard, O'Rourke, James, Schuster, David, Wong, Mark, Mrugala, Maciej, Jensen, Randy, Trusheim, John, Lesser, Glenn, Belanger, Karl, Sloan, Andrew, Purow, Benjamin, Fink, Karen, Raizer, Jeffrey, Schulder, Michael, Nair, Suresh, Peak, Scott, Perry, James, Brandes, Alba, Weller, Michael, Mohile, Nimish, Landolfi, Joseph, Olson, Jon, Finocchiaro, Gaetano, Jennens, Ross, DeSouza, Paul, Robinson, Bridget, Crittenden, Marka, Shih, Kent, Flowers, Alexandra, Ong, Shirley, Connelly, Jennifer, Hadjipanayis, Costas, Giglio, Pierre, Mott, Frank, Mathieu, David, Lessard, Nathalie, Sepulveda, Sanchez Juan, Lövey, József, Wheeler, Helen, Inglis, Po-Ling, Hardie, Claire, Bota, Daniela, Lesniak, Maciej, Portnow, Jana, Frankel, Bruce, Junck, Larry, Thompson, Reid, Berk, Lawrence, McGhie, John, Macdonald, David, Saran, Frank, Soffietti, Riccardo, Blumenthal, Deborah, André de, Sá Barreto Costa Marcos, Nowak, Anna, Singhal, Nimit, Hottinger, Andreas, Schmid, Andrea, Srkalovic, Gordan, Baskin, David, Fadul, Camilo, Nabors, Louis, LaRocca, Renato, Villano, John, Paleologos, Nina, Kavan, Petr, Pitz, Marshall, Thiessen, Brian, Idbaih, Ahmed, Frenel, Jean Sébastien, Domont, Julien, Grauer, Oliver, Hau, Peter, Marosi, Christine, Sroubek, Jan, Hovey, Elizabeth, Sridhar, P.S., Cher, Lawrence, Dunbar, Erin, Coyle, Thomas, Raymond, Jane, Barton, Kevin, Guarino, Michael, Raval, Sumul, Stea, Baldassarre, Dietrich, Jorge, Hopkins, Kirsten, Erridge, Sara, Steinbach, Joachim-Peter, Pineda, Losada Estela, Balana, Quintero Carmen, Sonia del, Barco Berron, Wenczl, Miklós, Molnár, Katalin, Hideghéty, Katalin, Lossos, Alexander, Myra van, Linde, Levy, Ana, Harrup, Rosemary, Patterson, William, Lwin, Zarnie, Sathornsumetee, Sith, Lee, E-Jian, Ho, Jih-Tsun, Emmons, Steven, Duic, J. Paul, Shao, Spencer, Ashamalla, Hani, Weaver, Michael, Lutzky, Jose, Avgeropoulos, Nicholas, Hanna, Wahid, Nadipuram, Mukund, Cecchi, Gary, O'Donnell, Robert, Pannullo, Susan, Carney, Jennifer, Hamilton, Mark, MacNeil, Mary, Beaney, Ronald, Fabbro, Michel, Schnell, Oliver, Fietkau, Rainer, Stockhammer, Guenther, Malinova, Bela, Odrazka, Karel, Sames, Martin, Miguel Gil, Gil, Razis, Evangelia, Lavrenkov, Konstantin, Castro, Guillermo, Ramirez, Francisco, Baldotto, Clarissa, Viola, Fabiana, Malheiros, Suzana, Lickliter, Jason, Gauden, Stanislaw, Dechaphunkul, Arunee, Thaipisuttikul, Iyavut, Thotathil, Ziad, Ma, Hsin-I, Cheng, Wen-Yu, Chang, Chin-Hong, Salas, Fernando, Dietrich, Pierre-Yves, Mamot, Christoph, Nayak, Lakshmi, Nag, Shona, Tran, David D, Recht, Lawrence D, Goldlust, Samuel A, O'Rourke, Donald M, Hamilton, Mark G, Wick, Wolfgang, Green, Jennifer, He, Yi, Turner, Christopher D, Yellin, Michael J, Keler, Tibor, Davis, Thomas A, Stupp, Roger, and Sampson, John H

Published
2017
Full Text
View/download PDF

42. Stroke death in patients receiving radiation for head and neck cancer in the modern era

Author

Hardy, Sara J., primary, Bandyopadhyay, Sanjukta, additional, Yang, Hongmei, additional, Williams, Annalynn, additional, Gudina, Abdi, additional, Cummings, Michael A., additional, Zhang, Hong, additional, Singh, Deepinder P., additional, Chen, Yuhchyau, additional, Mohile, Nimish A., additional, Janelsins, Michelle C., additional, and Milano, Michael T., additional

Published
2023
Full Text
View/download PDF

50. Contributors

Author

Abu-Arja, Rolla, primary, Aguilar-Bonilla, Ana, additional, Ahluwalia, Manmeet S., additional, Ali, Sheikh C., additional, Allen, Deborah H., additional, Alnahhas, Iyad, additional, Arnone, Gregory D., additional, Auquier, Pascal, additional, Avgeropoulos, Nicholas G., additional, Batich, Kristen A., additional, Baumstarck, Karine, additional, Bell, Susan D., additional, Benitez, Viviana, additional, Blumenthal, Deborah T., additional, Bornhorst, Miriam, additional, Boyer, Laurent, additional, Bramall, Alexa N., additional, Braun, Sarah, additional, Brem, Henry, additional, Broaddus, William C., additional, Broniscer, Alberto, additional, Butowski, Nicholas, additional, Cha, Soonmee, additional, Chamberlain, Marc C., additional, Chang, Susan, additional, Charest, Alain, additional, Chen, Zhi-Jian, additional, Chowdhary, Sajeel, additional, Clarke, Jennifer L., additional, Cohen, Adam L., additional, Colman, Howard, additional, Cooper, Michael, additional, Cotter, Jennifer, additional, Das, Sunit, additional, De, Kuntal, additional, De la Fuente, Macarena I., additional, Deo, Anand K., additional, Desjardins, Annick, additional, Dhall, Girish, additional, Doolittle, Nancy D., additional, Downey, Kira M., additional, Dunn, Gavin P., additional, Engelhard, Herbert H., additional, Ernoult, Emilie, additional, Everson, Richard G., additional, Fenstermaker, Robert A., additional, Ferry, Isabelle, additional, Figel, Sheila, additional, Fink, Karen L., additional, Finlay, Jonathan L., additional, Gernsback, Joanna E., additional, Giglio, Pierre, additional, Gorelick, Noah, additional, Haas-Kogan, Daphne, additional, Hachmann, Jan T., additional, Hashem, Hasan, additional, Henson, John W., additional, Huang, Sherri Y., additional, Huynh, Mai Anh, additional, Hwang, Eugene I., additional, Jackson, Eric, additional, Johanns, Tanner M., additional, Kahlon, Liron, additional, Kanojia, Deepak, additional, Karajannis, Matthias A., additional, Kaur, Balveen, additional, Kesari, Santosh, additional, Kilburn, Lindsay B., additional, Kim, Julius W., additional, Kline, Cassie, additional, Kolcun, John Paul G., additional, Komotar, Ricardo J., additional, Koshy, Matthew, additional, Kuzan-Fischer, Claudia M., additional, Lakka, Sajani S., additional, Lanoye, Autumn, additional, Lee, George P., additional, Lee, Eudocia Q., additional, Lesniak, Maciej S., additional, Liau, Linda M., additional, Loughan, Ashlee R., additional, Malkin, Mark G., additional, McCullough, Brendan J., additional, McGregor, John M., additional, Mehta, Ankit I., additional, Miller, Julie J., additional, Mohile, Nimish, additional, Moots, Paul L., additional, Mueller, Sabine, additional, Mukherjee, Joydeep, additional, Murillo, Tulio P., additional, Muroski, Megan E., additional, Neuwelt, Edward A., additional, Newton, Herbert B., additional, Nicholas, Martin K., additional, Oberheim Bush, Nancyann, additional, Okada, Hideho, additional, Omuro, Antonio M., additional, Packer, Roger J., additional, Paleologos, Nina A., additional, Panek, Wojciech K., additional, Pernal, Sebastian P., additional, Pickle, Emily Owens, additional, Pituch, Katarzyna C., additional, Pollack, Ian F., additional, Raizer, Jeffrey, additional, Rashidi, Aida, additional, Reardon, David A., additional, Reddy, Alyssa T., additional, Robert Kane, J., additional, Rutka, James T., additional, Sampson, John H., additional, Sattur, Mithun, additional, Scheck, Adrienne C., additional, Scott, Brian J., additional, See, Wendy L., additional, Shaikh, Nawal, additional, Sharma, Mayur, additional, Shokuhfar, Tolou, additional, Shroff, Seema, additional, Smith, Amy A., additional, Subramaniam, Subanandhini, additional, Suryadevara, Carter M., additional, Swanson, Kenneth D., additional, Tamrazi, Benita, additional, Taslimi, Shervin, additional, Teicher, Beverly, additional, Tran, Hung N., additional, Tyler, Betty, additional, Upadhyaya, Santhosh A., additional, Vega, Rafael A., additional, Venere, Monica, additional, Vogelbaum, Michael, additional, Von Ah, Diane, additional, Waissengrin, Barliz, additional, Waite, Emily S., additional, Wong, Eric T., additional, Xiao, Annie, additional, Yang, Jer-Yen, additional, Young, Jacob S., additional, Young Yoo, Ji, additional, and Zaky, Wafik, additional

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results